TIFFANY VILLAMARIN: Open Payments
NPI 1477265635 · WEST HARRISON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$859 in 38 payments from 20 companies in 2025. Trend: 2023 $766 · 2024 $2,014 · 2025 $859
Food & beverage: $859
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $138 |
| Celgene Corporation | 5 | $96 |
| Novartis Pharmaceuticals Corporation | 2 | $66 |
| Rigel Pharmaceuticals, Inc. | 2 | $55 |
| Incyte Corporation | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Eisai Inc. | 2 | $47 |
| PFIZER INC. | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Legend Biotech USA Inc. | 2 | $35 |
Products named: ENHERTU, Fabhalta, OPDIVO, REBLOZYL, TAVALISSE, NINLARO, Lenvima, TAGRISSO.
Industry payments across NY — which companies pay providers there.
